Skip to main content
Premium Trial:

Request an Annual Quote

Caprion, Idec Ink CellCarta Collab; Caprion Nabs $4M Equity Investment

NEW YORK, Sept. 17 - Caprion Pharmaceuticals today said it has signed an R&D deal with Idec Pharmaceuticals potentially worth $11 million.


The multi-year deal, which landed Caprion a $4 million equity investment, calls for Idec to use Caprion's CellCarta proteomics platform to identify tumor-specific cell-surface antigen targets. The drug discoverer will then use its monoclonal antibody and radioimmunotherapy technologies to develop therapeutics against those targets, the companies said.


Beside the $4 million equity investment, Caprion, based in Montreal, stands to earn up to $7 million in tech-access fees over the life of the collaboration. Neither company would specify the intended length of the deal. Certain undisclosed milestones will trigger additional payments to Caprion, the partners said.


Click here for more information.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more